Skip to main content
. Author manuscript; available in PMC: 2014 Sep 1.
Published in final edited form as: Am J Transplant. 2013 Jul 15;13(9):2280–2292. doi: 10.1111/ajt.12350

Fig 7.

Fig 7

Effect of delayed anti-CD154 or CTLA-4Ig administration on established GCs and developing alloantibody response. Anti-CD154 (500 μg/mouse) or CTLA-4Ig (500 μg/mouse) was administered starting on the day before (d0) or 7 days (d7) after immunization with BALB/c splenocytes. Positive controls were immunized, untreated (No Rx) mice. All groups receiving anti-CD154 or CTLA-4Ig demonstrated reduced (a) donor-specific antibodies and (b) reduced percentages and total numbers of GC Kd Tet-DP B cells at the end of the 28 day treatment period, compared to the immunized, untreated group. (c & d) Effect of delayed treatment with anti-CD154 or CTLA-4Ig from day 7-14 post-immunization on the percentage and total numbers of GC Kd-Tet DP cells. Untreated (No Rx) group were sacrificed on day 7 post-immunization. All data are the mean and SEM of 4-5 mice, and statistically significant differences are indicated (***p<0.001).